ClinicalTrials.gg
RecruitingNCT07051811Updated Jul 4, 2025

To Evaluate the Safety and Efficacy of a Single-Use IVUS Ablation for Primary Hypertension

An interventional study of Intravascular Ultrasound Ablation Therapy and Renal Artery Angiography in Essential Hypertension, sponsored by Lepu Medical Technology (Beijing) Co., Ltd.. Recruiting at 18 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-07-04.

Sponsored by Lepu Medical Technology (Beijing) Co., Ltd. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Feb 2025, registered Jun 2025).
  • Started Feb 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
213
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 76 studies in Essential Hypertension with a site in China — 19 open to participants now, 20 under way, 2 of them phase 3. Essential Hypertension · China.

Planned enrollment
39th of 67
213 · median 297
Started
2025
with 2 others
No phase
22 of 76
8 open now
Primary completion
2027-12
later than 16 of 19 live
Registered
67th of 76
by date
Lead sponsor
2 of 76
Lepu Medical Technology (Beijing) Co., Ltd.

Among the 76 studies in Essential Hypertension with a site in China, this one is the 39th largest by planned enrollment of the 67 interventional ones that give a count, is one of 3 that started in 2025, is one of 22 with no phase, reaches primary completion later than 16 of the 19 other live ones, and was the 67th registered.

Essential Hypertension

481 studies on the registry are indexed under Essential Hypertension; 75 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

19 of the 76 studies in Essential Hypertension with a site in China are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 43 Essential Hypertension studies recruiting now, 15 (35%) set no upper age limit and 20 (47%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Essential Hypertension with a site in China, or all of them as a file.
02

Study summary

This is a prospective, multicenter, blinded, randomized controlled clinical trial designed to evaluate the safety and efficacy of a single-use intravascular ultrasound ablation catheter and ultrasound ablation system in the treatment of primary hypertension.

Read the detailed description

This trial adopts a prospective, multicenter, randomized controlled design to validate the safety and efficacy of a single-use intravascular ultrasound ablation catheter and ultrasound ablation system in the treatment of primary hypertension. Subjects who signed the informed consent form will enter the screening phase and undergo a run-in period for 4-week of standardized medication regimen. Specifically, their current antihypertensive treatment will be uniformly replaced with a combination of an angiotensin II receptor blocker (ARB) and calcium channel blocker (CCB) (Valsartan/Amlodipine 80:5 mg) or a triple combination of ARB/CCB (Valsartan/Amlodipine 80:5 mg) plus a diuretic (Hydrochlorothiazide 12.5mg) . If the subject's office systolic blood pressure (SBP) ≥180 mmHg or diastolic blood pressure (DBP) ≥110 mmHg during the run-in period, the investigator may adjust the medication and restart a run-in period of ≥28 days. Blood pressure will be re-evaluated, and subjects failed to meet the inclusion criteria after adjustment will be excluded.

Subjects meeting the inclusion criteria and not violating exclusion criteria will be randomized in a 2:1 ratio to either the treatment group or the control group. The treatment group will undergo intravascular ultrasound ablation therapy, while the control group will only undergo renal artery angiography. Both groups will maintain the standardized medication regimen for 6 months post-procedure (if a subject's office SBP exceeds 180 mmHg or drops below 110 mmHg in three consecutive measurements spaced 1 hour apart, the investigator may adjust the medication and record their blood pressure before the adjustment).

The primary efficacy endpoint is the change in 24-hour average ambulatory systolic blood pressure at 6 months post-procedure. Results will be analyzed using a superiority testing hypothesis to demonstrate that the treatment group achieves significantly greater reduction in 24-hour mean ambulatory systolic blood pressure compared to the control group at 6-month follow-up. During follow-up, office blood pressure, 24-hour ambulatory blood pressure, medication usage, safety events, and adverse events will be recorded for both groups.

03

Conditions studied

  • Essential Hypertension
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged ≥18 years and ≤75 years, regardless of gender.
  2. Documented history of primary hypertension.
  3. Stable use of at least two antihypertensive medications for a minimum of 4 consecutive weeks prior to randomization, specifically requiring a combination of an angiotensin II receptor blocker (ARB) and a calcium channel blocker (CCB) or a triple combination of ARB/CCB plus a diuretic agent . After at least 4 consecutive weeks of screening, blood pressure must meet the following criteria:

    1. Office systolic blood pressure (SBP) ≥150 mmHg and \<180 mmHg;
    2. Office diastolic blood pressure (DBP) ≥90 mmHg;
    3. 24-hour ambulatory systolic blood pressure ≥135 mmHg and \<170 mmHg.
  4. Patients who can understand the purpose of the trial, voluntarily participate and sign the form, and are willing to comply with clinical follow-up.

Exclusion criteria

Exclusion Criteria:

  1. Unsuitable Renal Artery Anatomy for Treatment

    1. Main renal artery diameter \<4 mm or length \<20 mm.
    2. Accessory renal artery diameter ≥ 2 mm and \<4 mm.
    3. Renal artery stenosis >50% in the main renal artery.
    4. Renal artery aneurysm, fibromuscular dysplasia, or severe calcification.
    5. Presence of a renal artery stent.
    6. Single kidney.
  2. Estimated (eGFR) \<45 mL/min/1.73 m².
  3. Diagnosis of Type 1 Diabetes Mellitus.
  4. Orthostatic Hypotension.
  5. Recent Vascular Events:Acute myocardial infarction, unstable angina, syncope, or cerebrovascular accident within 3 months prior to signing the form.
  6. Suspected Secondary Hypertension.
  7. Respiratory Support:a) Requirement for long-term oxygen support or mechanical ventilation (excluding nocturnal respiratory support for sleep apnea).
  8. Prior Renal Artery Denervation Procedure.
  9. \<1 Year.
  10. Pregnancy, Lactation, or Plans to Become Pregnant Within 6 Months (for Females); Males Planning to Conceive Within 6 Months.
  11. Current Participation in Another Clinical Trial Without Completion of the Primary Endpoint.
  12. Allergy to Contrast Agents.
  13. Other Reasons Deemed by the Investigator to Make the Subject Unsuitable for Participation (e.g., Poor Compliance).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
213 participants (estimated)

Study arms

  • Experimental
    Renal denervation (RDN) Group

    Receive standardized treatment with a minimum of two drugs and renal denervation treatments (RDN)

    Procedure: Intravascular Ultrasound Ablation Therapy

  • Sham comparator
    Control Group

    Receive standardized treatment with a minimum of two drugs and renal artery angiography only

    Procedure: Renal Artery Angiography

Interventions

  • ProcedureIntravascular Ultrasound Ablation Therapy

    The single-use intravascular ultrasound ablation catheter is used in conjunction with the ultrasound ablation device to remove renal sympathetic nerves. Standardized medication regimen.

  • ProcedureRenal Artery Angiography

    Only undergo renal artery angiography. Standardized medication regimen.

06

What researchers measure

Primary outcomes

  1. Change in 24-hour average ambulatory systolic blood pressure (SBP) [at 6 months post-procedure]

    Time frame: From baseline to 6 months

Secondary outcomes

  1. Change in Daytime/Nighttime Average Ambulatory Systolic Blood Pressure (SBP)

    Time frame: 1 Month, 2 Months, and 6 Months Post-Procedure

  2. Change in 24-Hour/Daytime/Nighttime Average Ambulatory Diastolic Blood Pressure (DBP)

    Time frame: 1 Month, 2 Months, and 6 Months Post-Procedure

  3. Change in 24-Hour Average Ambulatory Systolic Blood Pressure (SBP)

    Time frame: 1 Month and 2 Months Post-Procedure

  4. Change in Office Systolic Blood Pressure

    Time frame: 1 Month, 2 Months, and 6 Months Post-Procedure

  5. Change in Office Diastolic Blood Pressure

    Time frame: 1 Month, 2 Months, and 6 Months Post-Procedure

  6. Achievement Rate of Target Office Systolic Blood Pressure

    Time frame: 1 Month, 2 Months, and 6 Months Post-Procedure

  7. Composite Index of Antihypertensive Medication Use

    Time frame: 1 Month, 2 Months, and 6 Months Post-Procedure

  8. Proportion of Subjects with ≥5 mmHg Reduction in 24-Hour Average Ambulatory Systolic Blood Pressure

    Time frame: 6 Months Post-Procedure

07

Study locations

15 of 18 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Dec 2027, 34 months after the start.

Of 80 interventional studies with no phase under Essential Hypertension, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 48. This study's planned 34 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2025
First posted
Jul 4, 2025
StartActual
Feb 25, 2025
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2029
Last update
Jul 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07051811
Responsible party
Sponsor
First posted
Jul 4, 2025
Start date
Feb 25, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Jul 4, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion